The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Boston Scientific missed estimates on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped and GAAP earnings per share dropped significantly.
Margins shrank across the board.
Boston Scientific reported revenue of $1.85 billion. The 23 analysts polled by S&P Capital IQ anticipated revenue of $1.91 billion. Sales were 7.7% lower than the prior-year quarter's $2.00 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.
Non-GAAP EPS came in at $0.08. The 25 earnings estimates compiled by S&P Capital IQ forecast $0.08 per share on the same basis. GAAP EPS of $0.07 for Q4 were 56% lower than the prior-year quarter's $0.16 per share.
Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.
For the quarter, gross margin was 62.5%, 320 basis points worse than the prior-year quarter. Operating margin was 11.3%, 260 basis points worse than the prior-year quarter. Net margin was 5.8%, 600 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $1.90 billion. On the bottom line, the average EPS estimate is $0.11.
Next year's average estimate for revenue is $7.63 billion. The average EPS estimate is $0.46.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 746 members rating the stock outperform, and 186 members rating it underperform. Among CAPS All-Stars (recommendations by the highest-ranked CAPS members), 181 give Boston Scientific a green thumbs-up, and 17 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Boston Scientific is hold, with an average price target of $6.93.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Boston Scientific the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Boston Scientific to My Watchlist.